

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
IL-15 and soluble IL-15 receptor α -chain (sIL-15RA) heterodimers	<p>Mouse studies suggest heterodimers of IL-15 and sIL-15RA could be more potent than IL-15 monomers for stimulating the immune system against diseases such as cancer. Cell lines that produce IL-15 and sIL-15RA were used to generate stable heterodimers of the molecules. In mice, the heterodimers showed longer half-life, higher plasma stability and more potent stimulation of lymphocyte proliferation than did IL-15 monomers. Next steps include scaling up the process to generate GMP material as well as a planned Phase I trial in cancer.</p> <p>SciBX 6(21); doi:10.1038/scibx.2013.533 Published online May 30, 2013</p>	<p>Patent application filed; licensed to Marine Polymer Technologies Inc.</p>	<p>Chertova, E. <i>et al. J. Biol. Chem.</i>; published online May 6, 2013; doi:10.1074/jbc.M113.461756 Contact: George N. Pavlakis, National Cancer Institute, Bethesda, Md. e-mail: pavlakig@mail.nih.gov</p>